Patients who have HRPC often have involvement of bone marrow, leading to symptoms such bone pain, spinal-cord compression and pathological fracture. Existing bone-targeted treatments, such as use of the beta-emitting radioisotope strontium-89 have been shown to reduce bone pain.
Dr Christopher Parker, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK and colleagues did a study of 64 patients with HRPC. Radium 223 was chosen because it emits alpha radiation – which has higher energy and travels less distance than the beta radiation. Thus Parker and colleagues believe that alpha radiation will have a more pronounced localised effect on tumours.
The patients were randomly assigned to two groups. In the first, 33 received external-beam radiotherapy and up to four injections of radium-223. The other group received the same radiotherapy and placebo.
Levels of bone alkaline phosphatase (bone-ALP) – considered a marker for progression of HRPC – decreased by 66% in the group receiving radium-223. The length of time for patients’ HRPC to progress - as assessed by each prostate-specific-antigen concentration – was much longer for those receiving radium 223 (26 weeks) compared to placebo (eight weeks). The median survival time for radium-223 patients was 41% longer than those receiving placebo (65.3 weeks vs 46.4 weeks respectively); and no Radium-223 patients stopped treatment due to treatment toxicity
However, radium-223 treatment had no significant effect on the timing of skeletal related events (SREs) – another key indicator of HRPC progression. These include, among other factors, a 25% increase in pain severity, increased painkiller consumption, new pathological bone fractures, tumour related orthopaedic surgical intervention, and use of radioisotopes to relieve new skeletal related symptoms.
The authors believe larger clinical trials are needed to study the effect of radium-223 on SREs and overall survival rates for HRPC.
The authors say: “In our randomised study of patients with symptomatic, hormone-refractory prostate cancer, radium-223 was well tolerated with little or no myelotoxic effect, and showed promising evidence of efficacy.”
They conclude: “Further studies of radium-223 should explore potential for escalation of dose and for increased duration of treatment by more than four injections. The bone targeting properties of Radium-223 could also be applicable to the treatment of skeletal metastasis from other primary cancers.”
Tony Kirby | alfa
Dengue takes low and slow approach to replication
12.01.2018 | Duke University
Fast food makes the immune system more aggressive in the long term
12.01.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...
Scientists at Helmholtz Zentrum München have discovered a mechanism that amplifies the autoimmune reaction in an early stage of pancreatic islet autoimmunity prior to the progression to clinical type 1 diabetes. If the researchers blocked the corresponding molecules, the immune system was significantly less active. The study was conducted under the auspices of the German Center for Diabetes Research (DZD) and was published in the journal ‘Science Translational Medicine’.
Type 1 diabetes is the most common metabolic disease in childhood and adolescence. In this disease, the body's own immune system attacks and destroys the...
15.01.2018 | Event News
08.01.2018 | Event News
11.12.2017 | Event News
15.01.2018 | Physics and Astronomy
15.01.2018 | Life Sciences
15.01.2018 | Life Sciences